title: Prevalence and significance of antiphospholipid antibodies in selected at-risk obstetrics cases: a comparative prospective study.
abstract: In a prospective comparative study we screened 112 women with a past history either of pre-eclampsia, eclampsia, recurrent abortion, IUGR, IUFD or abruptio placentae, with no apparent aetiology and a demographically matched cohort of 106 women having a past history of uncomplicated pregnancy outcome for the presence of antiphospholipid antibodies (aPL) and their significance. In the former group, the prevalence of aPL ranged from 10-46.87% compared with 8.49% in the later group. In women with the presence of aPL, the incidence of pre-eclampsia, early onset pre-eclampsia and abruptio placentae were 25%, 14.58% and 18.75%, respectively. In the same group, the abortion rate was 25% and live-birth rate was 64.58% with IUFD rate of 10.42%. Fetal morbidity rates were also higher in the mothers with aPL positivity, the incidence of IUGR was 27.08% and oligohydramnios was 33.33% in them. All these complications were statistically significant when compared with those of aPL negative mothers.
authors.affiliation: Department of Obstetrics and Gynaecology, North Bengal Medical College, Sushrutanagar, West Bengal, Darjeeling, India. drsps94@gmail.com
authors.forename: S P
authors.initials: SP
authors.lastname: Saha
authors.forename: N
authors.initials: N
authors.lastname: Bhattacharjee
authors.forename: R P
authors.initials: RP
authors.lastname: Ganguli
authors.forename: S
authors.initials: S
authors.lastname: Sil
authors.forename: K K
authors.initials: KK
authors.lastname: Patra
authors.forename: M
authors.initials: M
authors.lastname: Sengupta
authors.forename: G
authors.initials: G
authors.lastname: Barui
authors.forename: B K
authors.initials: BK
authors.lastname: Goswami
mesh_terms: D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D016682:Lupus Coagulation Inhibitor / Q000097:blood*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000453:epidemiology / Q000276:immunology*; D011256:Pregnancy Outcome; D015995:Prevalence; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D017153:Antibodies, Anticardiolipin; D016682:Lupus Coagulation Inhibitor